Bicine,

BICINE is a compound containing a tertiary amino group whose relevant pAT is 8.3 (Figure 2.18). Given 1 L of 0.05 M BICINE with its tertiary amino group in the uiiprotoiiated form, how much O.l N HCl must be added to have a BICINE buffer solution of pH 7.5 What is the molarity of BICINE in the final buffer ... 

Equilibrium studies in water were performed for [Mc2Sn(IV)] complexes of zwitterion buffers, such as bicine and tricine (L). The results showed the formation of MLH, ML, ML2, MLH i, and MLH 2 with the hydrolysis products of the... 

Trail, P.A., Willner, D., Lasch, S.J., Henderson, A.J., Hofstead, S., Casazza, A.M., Firestone, R.A., Hellstrom, I., and Hellstrom, K.E. (1993) Cure of xenografted human carcinomas by BR96-doxoru-bicin immunoconjugates. Science 261, 212-215. 

Less direct evidence for active transport mechanisms includes the high degree of absorption of the P-gp substrate losartan in the isolated perfused rat lung, which indicated an absence of any absorption-retarding effect of P-gp [139], Evidence to the contrary includes an increase in the uptake of idaru-bicin when administered to the IPL via the perfusate in the presence of P-gp inhibitors [70],... 

N-Morpholino]propanesulfonic acid (MOPS) N-[2-Hydroxyethyl]piperazine-N -[2-ethanesulfonic acid] (HEPES) N,N-bis[2-Hydroxyethyl]glycine (BICINE)... 

Figure 6 Transmission electron microscopic picture of nanoparticles containing PLGA-doxoru-bicin conjugates. Scale bar is 2 p.m in (A) and 200 nm in (B) (adapted with permission from the publisher [24]). 

UGTIAI has an important role in the metabolism of irinotecan, etoposide, epiru-bicine, and tipifamib. Irinotecan is a camptothecin derivative used in the treatment of metastatic colon cancer. Irinotecan is a prodrug since it is activated to Ethyl-10-hydroxycamptothecin (SN-38) by carboxyl esterase to exert its antitumor activity mediated by the inhibition of topoisomerase I. SN-38 undergoes UGTIAI-catalyzed glucuronide conjugation to form the inactive SN-38 glucuronide (SN-38G). 

EPPS, also called HEPPS) N-Tris(hydroxymethyl)methyl-glycine (Tricine) N,N-Bis(2-hydroxyethyl)glycine (Bicine)... 

H blottingbuffer 20-fold 0.5 M Bicine (N,N-bis(2-hydroxyethyl)-glycine), 0.5 M Bis-Tris, 20 mM EDTA Mix the gel according to Table 2.3 and pour it into the cassette. 

Figure 7.17 Hydrolysis of oleic anhydride catalyzed by spontaneously formed oleic acid vesicles at 40 °C, (a) during the first 3 h, and (b) during a long observation time. A vesicle suspension (10 ml in 0.2 M bicine buffer (pH 8.5)) was overlaid with 0.25 mmol oleic anhydride and 0.025 mmol oleic acid. The increase of the concentration of oleic acid/oleate is plotted as a function of reaction time. Initial concentration of oleic acid/oleate 0 mM ( ), 5 mM ( ), 10 mM (o), 20 mM ( ). For an initial oleic acid/oleate concentration of 20 mM, the concentration of oleic anhydride (A) present in the vesicles during the reaction is also plotted (b, right axis). (From Walde et al, 1994b.)...

Figure 10.15 Intensity-weighted size distribution of POPC in 0.2 M bicine buffer solution, pH 8.5 0.5 ml solution of 1 mM 30 nm extruded POPC vesicles mixed with 0.5 ml solution of 1 mM 200 nm extruded POPC vesicles. The measuring angle is 90°. (From Cheng and Luisi, 2003.)...

Figure 10.16 Effect of Ca + on the turbidity change upon mixing oleate vesicle solutions 0.25 ml 1 mM 60 nm radius extruded oleic acid vesicles + 0.25 ml 1 mM 200 nm radius extruded oleic acid vesicles + 1.5 ml bicine buffer. Calcium ion concentration (a) 0 mM (b) 1 irtM (c) 2.5 mM (d) 5 mM (e) added excess EDTA to (d). (Adapted from Cheng and Luisi, 2003.)...

Figure 10.19 Effect of pre-added vesicles on the formation of oleic acid/oleate vesicles. Turbidity measured at 500 nm (1 cm path length) is plotted as a function of time, T=2°C. (a) 62 p,l of 80 mM aqueous sodium oleate was added to 2.438 ml of0.2Mbicine buffer, pH 8.8 ([oleic acid/oleate] = 2 mM). (b)62 p,l of 80mM aqueous sodium oleate was added to 2.438 ml of a 2 mM oleic acid/oleate 100 nm vesicle suspension (0.2 M bicine buffer, pH 8.8 ([oleic acid/oleate] = 4 mM). (c) Turbidity of 2 mM oleic acid/oleate 100 nm vesicles , (d) the same as (b), but using a 50 nm vesicle suspension, (e) Turbidity of 2 mM oleic acid/oleate 50 nm vesicles . (Modified from Blochiger etal, 1998.)...

G. Other applications Herceptin has been combined with cisplatin in the treatment of heavily pretreated metastatic breast cancer. Treatment of patients with ovarian cancer is under investigation. A recent study demonstrated that Herceptin increased the clinical benefits of first-line chemotherapy—doxorubicin (or epiru-bicin) and cyclophosphamide or pacli-taxel—in metastatic breast cancer that overexpressed HER2. 

---